Admission: LungLife AI Inc.
LungLife AI Inc. (LungLife) is a developer of clinical diagnostic solutions. These are designed to make significant improvements in the early detection of lung cancer.
LungLife’s diagnostic solution, the LungLB® test, is an AI-enhanced, blood-based test to stratify cancerous and benign lung nodules identified by CT scans. The test is intended to provide doctors with additional information to help the decision-making process for patients’ treatment.
LungLife has completed a pilot study to evaluate the LungLB® test and is now gearing up to proceed to a larger, multi-centre validation study ahead of seeking FDA approval. Through collaboration with major cancer medical centres, the directors believe that LungLife can effectively commercialise its tests for sale in the United States during 2023.
Crowe's role and team
Crowe acted as reporting accountant on the transaction. The capital markets team was led by Mitesh Patelia, George Lawford and James Leyton.
Client quote
"We were delighted to work with Crowe as part of our listing process. Their knowledge of both our sector and US companies was beneficial.”
Paul Pagano, Chief Executive Officer, LungLife AI Inc.
